Objective. The DETECT algorithm was developed for screening patients with SSc at high risk of pulmonary arterial hypertension (PAH). We evaluated the impact of this algorithm in a SSc population.
Introduction
SSc is a progressive autoimmune disorder characterized by fibrosis of the skin and internal organs, obliterative vascular pathology and distinct serum autoantibodies [1, 2] . SSc is associated with high mortality; the major cause of death is pre-capillary pulmonary hypertension (PH) [36] . The onset of PH in SSc is insidious, and it is often diagnosed late, with advanced stage vessel pathology [7] . The dominant forms of pre-capillary PH in SSc are pulmonary arterial hypertension (PAH), which is amenable to therapy (see below), and PH secondary to interstitial lung disease (ILD), which is less responsive to treatment [8, 9] .
Recent studies have indicated that, in SSc-associated PAH, the effects of targeted PAH therapies on outcome appear to be most pronounced in patients with early stage PAH [10] . Therefore, it is crucial to diagnose PAH as early as possible. The European Society of Cardiology and the European Respiratory Society (ESC/ERS) guidelines from 2009 suggested that patients with symptomatic SSc should be screened with echocardiography (ECHO) to determine the risk of PAH. These guidelines were modified in 2015, to recommend annual screening with ECHO for all patients with SSc [11, 12] . In 2014, an evidence-based PAH screening algorithm was developed (DETECT) to identify patients with PAH at asymptomatic stages [13] . The authors demonstrated that DETECT could detect PAH with higher sensitivity than the ESC/ERS 2009 guidelines [13] .
The gold standard criterion for PH diagnosis is a right heart catheterization (RHC) that demonstrates a mean pulmonary arterial pressure (mPAP) 525 mmHg [12] . However, the mPAP threshold of 25 mmHg was extrapolated primarily from early data and expert opinion, originally published four decades ago, and currently, this threshold is mostly considered arbitrary [14] . Measurements in healthy individuals have shown that the normal resting mPAP is within the range of 1417 mmHg, with very few outliers [15] . The clinical relevance of mPAP values in the upper normal range remains unknown, but mPAP >17 mmHg was shown to be associated with adverse events and reduced survival [15] . An analysis of RHC data obtained from the National Clinical Quality Program for All Veterans in the United States (the VA-CART national haemodynamic database) demonstrated that borderline PH, defined as mPAP = 19 À 24 mmHg, was a common independent risk factor for adverse clinical outcomes and mortality [16] . In SSc, borderline elevations of mPAP were shown to be associated with decreased exercise capacity and a high risk of developing PAH within a few years [17] . However, there are no guidelines for following up or treating patients with mPAP values that indicate borderline PH.
The present study aimed to: evaluate the incidence of PAH and borderline PH in an unselected SSc cohort, before and after implementation of the DETECT algorithm; assess the WHO functional class of patients with borderline PH and PAH; and stratify patients with borderline PH and PAH in the risk groups defined by the 2015 ESC/ERS guidelines.
Methods

Study cohort and clinical parameters
At the Oslo University Hospital (OUH), all patients with SSc are included in an ongoing, prospective, observational SSc cohort. All patients are followed by rheumatologists at OUH, and clinical, laboratory and imaging parameters are systematically recorded in the Norwegian Systemic Connective Tissue Disease and Vasculitis Registry [18] . The current study included all patients from the OUH SSc cohort that met the 2013 EULAR/ ACR classification criteria for SSc and had undergone a primary, diagnostic RHC in the period of January 2009 to March 2017 [19] . The study cohort was divided into two groups: patients that underwent a first RHC in January 2009 to December 2013 (Early cohort), and patients that underwent a primary RHC in January 2014 to March 2017 (DETECT cohort). The DETECT cohort comprised patients that were additionally screened for PH with the DETECT algorithm [13] . Data on patient demographics, clinical parameters and SSc subsets were retrieved from the Norwegian Systemic Connective Tissue Disease and Vasculitis Registry [18] . SSc subsets were defined as lcSSc and dcSSc [20] . The observation period was defined as the time from the incident RHC until the study end, in June 2017, or death. The time to follow-up RHC was defined as the time from the incident RHC to the follow-up RHC.
This study complied with the Declaration of Helsinki. The Regional Committee of Health and Medical Research Ethics in South-East Norway approved the research protocol (No.2006/119). Informed consent was obtained from all included subjects.
PH surveillance
In the time period from 2009 to 2013, the OUH protocol for PH surveillance in SSc included annual visits with a complete clinical examination, an ECHO, which provided an estimated systolic pulmonary arterial pressure, pulmonary function tests, a 6-min walking distance test and a measurement of N-terminal pro-brain natriuretic peptide (NT-proBNP). A referral for RHC was indicated when the clinical assessment pointed to a suspicion of PH, typically due to increasing or unexplained dyspnoea, a significant decline in the percentage of diffusing lung capacity for carbon monoxide (DLCO%), increasing NT-proBNP levels and a systolic pressure >40 mmHg on the ECHO. In January 2014, the DETECT algorithm was added to the OUH-SSc protocol, and all patients were referred to RHC when the DETECT score was >35.
RHC procedures and diagnostic procedures
A primary, diagnostic RHC was performed in all included patients from January 2009 to March 2017, with a SwanGanz pulmonary artery thermodilution catheter (Baxter Health Care Corp, Santa Ana, CA, USA). A follow-up RHC was conducted when clinically indicated. The mPAP and mean pulmonary capillary wedge (PCW) pressure were recorded (mmHg), cardiac output was measured with thermodilution, and the cardiac index was calculated by dividing cardiac output by the body surface area [21] . PCW was documented according to existing guidelines with breath holding close to endexpiration.
PH was diagnosed, according to the updated European Society of Cardiology guidelines, as a mPAP 525 mmHg, measured with RHC. The diagnosis was further divided into pre-and postcapillary PH, based on a threshold PCW of 15 mmHg [12, 22] . Borderline PH was defined as a mPAP of 2024 mmHg [16, 22] . The PH diagnosis was performed by an experienced cardiologist. The criteria for a PAH (WHO group 1) diagnosis were: (i) the presence of precapillary PH; (ii) the absence of significant ILD, based on high resolution CT (HRCT) and/or a pulmonary function tests; absence of ILD was demonstrated by < 10% lung fibrosis on the HRCT at baseline and follow-up investigations and/or by a predicted percentage forced vital capacity (FVC%) >70% at baseline and follow-up; and (iii) other causes of pre-capillary PH could be excluded [23, 24] . The PH-ILD (WHO group 3) diagnosis was defined as precapillary PH combined with findings of lung fibrosis >10% with HRCT and/or FVC <70%. Angina pectoris and myocardial infarction were recorded when present.
Risk stratification at the time of PAH diagnosis was estimated with the low, intermediate and high risk grouping system defined in the 2015 European Society of Cardiology recommendations for PAH [12] . Patients with 51 parameter of poor prognosis were considered at high risk; those with 51 parameter of intermediate prognosis were considered at intermediate risk. WHO functional classes (FC 14) , established by the New York Heart Association, were assessed in all patients at the time of RHC. 
Results
Study cohort
The total study cohort included 161 patients with SSc that had undergone a primary, diagnostic (incident) RHC at OUH during the study period, from January 2009 to March 2017. The mean age at inclusion was 61 (11.8) years, and the mean observation period was 2.9 (2.4) years. The cohort comprised 126 (78.8%) females, and 78 patients (48.8%) were ACA positive ( Trends in RHC frequency and diagnostic outcome over the study period
In addition to the incident RHC, at least one follow-up RHC procedure was performed in 69 (42.9%) patients from the study cohort, including 49 (63.6%) in the Early cohort and 20 (23.8%) in the DETECT cohort. The number of incident and follow-up RHCs conducted per year throughout the study period increased after 2013 (supplementary Fig. S1 , available at Rheumatology Online). The outcomes of these RHC investigations (no PH, borderline PH or PAH) are shown in Fig. 1 . The distribution of mPAP values (<17, 1720, 2024 or >25 mmHg) in the two cohorts were: n = 16 (20.8%), n = 13 (16.9%), n = 13 (16.9%) and n = 35 (45.5%), respectively, in the Early cohort, compared with n = 15 (19.3%), n = 10 (12%), n = 28 (33.7%) and n = 30 (36.1%), respectively, in the DETECT cohort (P = 0.146).
Results from the incident RHC in the Early and DETECT cohorts
The incident RHC was diagnostic for PAH in 16 (20.8%) patients in the Early cohort and 15 (17.9%) patients in the DETECT cohort (Table 1 ). There were no significant differences between the cohorts in the haemodynamic parameters at the incident RHC (supplementary Table S1 , available at Rheumatology Online).
In the Early cohort, 13 (16.9%) patients were diagnosed with borderline PH, compared with 26 (31.0%) patients in the DETECT cohort ( Table 1 ). The corresponding mPAP values were 22.9 (1.2) mmHg and 21.8 (1.5) mmHg, respectively; P = 0.019 (Table 2 ).
In the DETECT cohort, 28 patients (37.7%) had mPAPs <20 mmHg (no PH). These patients had significantly lower FVC/DLCO ratios, lower frequencies of systolic pulmonary arterial pressure >40 mmHg, higher frequencies of DLCO >60%, lower NT-proBNP levels and lower FCs than patients diagnosed with PH at the time of a referral for RHC (Table 3) . Moreover, the DETECT cohort had 46 (54.8%) patients with a DLCO <60% and 53 (64.3%) patients with a disease duration >3 years (measured from disease onset at the time of referral for RHC; Table 3 ). We also found that the DETECT scores calculated before referral to RHC differed significantly between the mPAP subgroups measured at the incident RHC (P < 0.001) (supplementary Fig. S2 , available at Rheumatology Online).
Functional status and risk assessment in patients with PAH or borderline PH At the time of the PAH diagnosis, the Early and DETECT cohorts were similar in New York Heart Association functional classes and risk stratifications, according to the 2015 ESC/ERS guidelines. In the DETECT cohort, four patients (26.7%) were at low risk, seven (46.7%) were at intermediate risk and four (26.7%) were at high risk of PAH poor prognosis. Corresponding numbers in the Early cohort were three (18.8%), six (37.5%) and seven (43.8%), respectively ( Fig. 2A and B) . Distribution of the clinical features for risk stratification is shown in supplementary Table S2 , available at Rheumatology Online.
At the time of the borderline PH diagnosis, a trend of improvement in functional class and significantly lower risk levels were observed in the DETECT cohort compared with the Early cohort. Specifically, in the Early cohort, two patients (22.2%) were at low risk, six (66.7%) were at intermediate risk and one patient (11.1%) was at high risk of PAH poor prognosis. Corresponding numbers in the DETECT cohort for patients at low, intermediate or high risk were 13 (59.1%), nine (40.9%) and zero (0%), respectively; P = 0.030 ( Fig. 2C and D) .
Results from the follow-up RHC in the study cohort
In the Early cohort, 26 patients (63%) had borderline or no PH on the incident RHC. These patients were subjected to a follow-up RHC after a mean of 2.4 (1.8) years (Fig. 3, left  panel) . The follow up RHC results showed that, among the 10 patients with borderline PH on the incident RHC, five (38.5%) developed PH after a mean of 2.2 (1.6) years. Among the 16 patients with no PH, eight (28.6%) developed borderline PH after a mean of 2.6 (2.3) years, and four (14.3%) developed PH after a mean of 3 (1.2) years (Fig. 3) . Of the remaining 15 patients with SSc in the Early cohort that did not undergo a follow-up RHC, four patients died, five were followed at their local department of rheumatology, five were clinically stable and one is currently awaiting a follow-up RHC, due to suspicion of PH development. Of the 77 patients with SSc in the Early cohort, 27 patients (35.1%) died during the observation period; the proportions of deaths were not significantly different among the PH subgroups.
In the DETECT cohort, seven patients (13%) underwent a follow-up RHC after a mean of 0.7 (0.7) years after the incident RHC (Fig. 3) . Due to the short follow-up time and few patients, no further analyses or comparisons were conducted within the DETECT cohort, regarding new onset PH or survival.
Discussion
There is a need to improve the early diagnosis of PAH in SSc to optimize treatment effects and improve survival.
FIG. 1 Frequencies of PAH, borderline PH and no PH
Numbers of patients, from 2009 until 2016, diagnosed with PAH (red line), borderline PH (blue line) or no PH (normal mean arterial pressure; green line) at the time of right heart catheterization. PAH: pulmonary arterial hypertension, PH: pulmonary hypertension.
The DETECT algorithm was established in 2014, with the intention of identifying patients with PAH at asymptomatic stages. Our results indicated that, after the introduction of DETECT, the incidence of PAH was stable, but the number of cases diagnosed with borderline PH increased significantly. Interestingly, we also found that, after DETECT was established, patients with borderline PH had significantly lower risk scores at diagnosis than patients with borderline PH identified in the Early, pre-DETECT cohort.
To our knowledge, this study was the first to compare the relative frequencies of PAH and borderline PH in a population-based SSc cohort before and after the introduction of the DETECT algorithm. Other studies focused on the sensitivity and specificity of DETECT. Those studies demonstrated the benefits of DETECT, compared 9.7 (11.3) 6.3 (6.2) 6.7 (7.6) 3.9 (3.9) 0.330 Onset to RHC >3 years, n (%) 17 Clinical characteristics of 84 patients with SSc in the DETECT cohort, prior to a referral for right heart catheterization (RHC), segregated according to the outcome of the incident RHC. a Significant findings in an ad hoc test compared with no PH. P-values were tested with one-way ANOVA. *significant findings in an ad hoc test compared to no PH. 6MWD: 6-min walking distance; DLCO: diffusing lung capacity for carbon monoxide; FC: functional class; FVC: forced vital capacity; NT-proBNP: Nterminal pro-brain natriuretic peptide; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; PH-ILD: interstitial lung disease associated pulmonary hypertension; post-capPH: post-capillary PH; RHC: right heart catheterization; sPAP: systolic pulmonary arterial pressure measured on ECHO.
with the ESC/ERS screening guidelines for PAH [2527] and borderline PH [25, 28] . In our clinical practice, we found no change in the PAH incidence after introducing the DETECT algorithm for PH surveillance. However, we did find that the number of new borderline PH cases increased significantly after including the DETECT algorithm; this increase was accompanied by a concomitant shift in the 2015 ESC/ERS risk score distribution [12] . We are aware that these risk scores were primarily developed for PAH, rather than borderline PH; however, because the mPAP threshold of 25 mmHg was mostly an arbitrary value, and considering the fact that mortality increased in patients with borderline PH, it is clinically important to identify patients with mPAP values of 2025 mmHg and consider their risk scores [14, 17] . However, the predictive value of risk scores in patients with SSc-related borderline PH remains to be confirmed with larger, prospective studies, preferably in population-based cohorts.
Another interesting finding is the lower percentage of cases with PH-ILD in the DETECT cohort compared with Flowchart of follow-up right heart catheterization (RHC) in patients with SSc without pulmonary hypertension (no PH) and with borderline PH at baseline in the Early and DETECT cohorts. PH: pulmonary hypertension.
the Early cohort. We do not know the exact reason, but it appears likely that the reduction reflects a change in the RHC referral pattern, with relatively fewer referrals of patients with severe lung fibrosis. Of note, we added the DETECT algorithm to annual PH screening in our clinical practice. Therefore, the DETECT algorithm was also performed in patients with DLCO >60%. We are aware that DETECT has not been validated for those patients, but it was unavoidable, because we included all patients with SSc that were considered at PH risk, based on clinical assessments at the annual PH screening.
The current study reinforced the notion that patients with SSc and borderline PH are at high risk of developing PAH. In fact, we observed a frequency of 38.5% PAH development after 2.4 years; that frequency was within the range observed in previous studies. In a large UK cohort, 30% of patients with SSc and borderline PH developed PAH. Additionally, in the PHAROS cohort, 55% of patients with borderline PH developed PAH [29, 30] . Given this high risk and the high mortality rate of established PAH, it is a sobering thought that there are no guidelines for following up borderline PH, and there have been no randomized trials on testing strategies for PAH prevention [10, 22, 31, 32] .
In animal models, PAH was shown to be driven by inflammatory responses. Local immune activation led to the dysfunction of vascular endothelial cells and smooth muscle cells, which resulted in neo-intimal hyperplasia in small pulmonary arteries [33] . In these models, it was shown that immune-modulation with MMF (a purine inhibitor), which was approved for organ transplantation, could attenuate the development of PAH [34, 35] . It is unknown whether MMF could prevent PAH development in SSc more efficiently than the approved PAH therapies, which target the vascular component of PAH. The latter therapies aim to maximize the properties of vessels. Nevertheless, it is interesting to note that preliminary data from the OUH SSc cohort indicated that the frequency of PAH in patients with SSc was reduced in a subset of patients that had received MMF treatment for skin/lung disease. Randomized clinical trials are warranted to determine whether PAH is preventable in borderline PH and, eventually, to determine optimal prevention strategies.
The current study reinforced the notion that the DETECT algorithm has high sensitivity. However, in this study, when we added the algorithm to our clinical screening programme, it had rather low specificity. Nevertheless, our findings suggested that an annual PAH screening programme that included DETECT would be likely to increase the total number of RHC investigations and increase the frequency of patients with SSc that have normal or borderline mPAP. Borderline mPAP justifies an early RHC follow-up, but prospective, randomized clinical trials are necessary to determine whether patients with borderline PH would benefit from this strategy. To avoid unnecessary invasive RHC procedures and to identify patients most likely to develop PH, additional, more specific PAH markers are needed that are suitable for integrating into clinical follow-up procedures, including the DETECT algorithm.
Our study had some limitations. First, a follow-up RHC was not performed in the entire SSc cohort, and second, the follow-up period was rather short for the DETECT cohort. The frequency of borderline PH and PAH was rather low, because the OUH cohort was populationbased, which covered the whole spectrum of disease. Larger, prospective studies, preferably in populationbased cohorts, are needed. The strengths of our study were that our study prospectively enrolled patients with SSc over a 9-year period, and all included patients had undergone an incident RHC. Additionally, we compared the frequencies of PAH and borderline PH in two cohorts, before and after including the DETECT algorithm in the annual PH screening programme.
In conclusion, we showed that the number of new PAH cases per year has been stable since 2009, with no apparent change after introducing the DETECT algorithm into PH screening. Starting in 2014, we observed a non-significant increase in the number of newly diagnosed PAH cases at low risk and better functional class status. The total number of RHCs increased, starting in 2014, with a concomitant increase in the number of borderline PH cases.
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